Clinical Trials Logo

Filter by:
NCT ID: NCT01009463 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 25, 2009
Phase: Phase 3
Study type: Interventional

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT01009255 Completed - Alzheimer's Disease Clinical Trials

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

Start date: November 2, 2009
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease

NCT ID: NCT01008852 Completed - Clinical trials for Active Rheumatoid Arthritis

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

Start date: December 2009
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.

NCT ID: NCT01005992 Not yet recruiting - Scar Clinical Trials

Fractional Photothermolysis for the Treatment of Burn Scars

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The aim of our study is to determine the effect of fractional photothermolysis laser in the treatment of burn scars.

NCT ID: NCT01003990 Completed - HIV Clinical Trials

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Start date: October 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial

NCT ID: NCT01000727 Completed - Clinical trials for Acute Coronary Syndrome

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

SOLID-TIMI 52
Start date: December 2009
Phase: Phase 3
Study type: Interventional

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

NCT ID: NCT01000506 Completed - Asthma Clinical Trials

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

DREAM
Start date: November 1, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.

NCT ID: NCT00998998 Completed - Clinical trials for Iron Deficiency Anemia

The Anemia Control Program: Early Intervention

Start date: April 1992
Phase: N/A
Study type: Interventional

The purpose of this study was to determine if a home-based intervention to foster child development improved behavior and development in infants with IDA.

NCT ID: NCT00998764 Terminated - Alzheimer Disease Clinical Trials

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

NCT ID: NCT00996918 Terminated - Alzheimer Disease Clinical Trials

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.